Yoshimasa Tokuchi
Hokkaido University(JP)Miwa Hospital(JP)Hakodate National Hospital(JP)
Publications by Year
Research Areas
Liver Disease Diagnosis and Treatment, Hepatocellular Carcinoma Treatment and Prognosis, Hepatitis C virus research, Systemic Lupus Erythematosus Research, Liver Disease and Transplantation
Most-Cited Works
- → Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria(2021)32 cited
- → Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication(2022)25 cited
- → Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment(2022)24 cited
- → Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150(2022)20 cited
- → Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation‐related hepatitis(2023)18 cited
- → Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI(2021)17 cited
- → Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C(2021)15 cited
- → Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma(2023)15 cited
- → Hepatitis C virus eradication by direct‐acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low‐density lipoprotein cholesterolemia without an increase in body weight(2023)14 cited
- → Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma(2022)12 cited